Profile data is unavailable for this security.

About the company

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.

  • Revenue in USD (TTM)22.56bn
  • Net income in USD4.98bn
  • Incorporated1933
  • Employees23.30k
  • Location
    Bristol-Myers Squibb Co430 E 29th St Fl 14NEW YORK 10016-8367United StatesUSA
  • Phone+1 (212) 546-4000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.bms.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
BMY:NYQ since
Celgene CorpAnnounced03 Jan 201903 Jan 2019Announced-13.18%79.38bn
Data delayed at least 15 minutes, as of Apr 18 2019 21:02 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Vertex Pharmaceuticals Incorporated3.05bn536.40m42.99bn2.50k81.349.6771.7114.112.078.0711.7517.380.62253.478.821,219,039.0010.77-5.1113.43-6.6586.5688.1817.30-8.993.3219.820.1177--22.4620.25103.80--13.20--
Biogen Inc13.45bn4.45bn44.53bn7.80k10.423.427.913.3121.7221.6065.5466.120.54981.985.601,724,731.0018.3818.8021.2721.9286.5087.2733.4332.272.0437.910.3130.009.6114.1819.9819.05-24.06--
Allergan plc15.79bn-5.16bn46.69bn16.90k--0.716729.152.96-15.37-15.3346.85195.770.14342.505.47934,165.70-4.63-3.61-4.99-3.8986.1283.23-32.31-28.240.98270.29530.2676---0.961743.4124.17---3.81--
Zoetis Inc5.83bn1.38bn47.45bn10.00k34.8621.7428.138.152.842.9311.964.560.60171.345.73582,500.0014.2410.6516.1912.7567.6766.0523.6716.422.468.810.74723.639.765.0128.5322.3712.9320.91
Celgene Corporation15.28bn4.05bn65.86bn8.85k16.9410.6614.074.315.535.5320.838.800.46571.187.671,726,277.0012.3310.9113.8112.1696.1695.9426.4824.552.1214.730.76690.0017.5218.67-3.8722.7818.86--
Bristol-Myers Squibb Co22.56bn4.98bn74.38bn23.30k14.985.2713.043.303.043.0013.788.640.65845.455.02968,283.3014.6010.0520.7913.9271.4973.8722.1817.901.5018.370.342274.948.596.6127.4914.1912.112.71
Gilead Sciences, Inc.22.13bn5.46bn80.25bn11.00k15.123.7711.643.634.164.1616.9316.680.33046.016.172,011,546.008.1623.089.8028.2278.0784.3724.6943.523.307.600.559217.01-15.2414.59-46.0612.1737.10--
Amgen, Inc.23.75bn8.39bn109.31bn21.50k14.088.9410.574.6012.6012.6035.7019.850.32451.426.971,104,512.0011.479.9613.5511.4282.7381.1535.3532.602.5714.290.730840.323.934.923.9010.561.2722.94
Data as of Apr 18 2019. Currency figures normalised to Bristol-Myers Squibb Co's reporting currency: US Dollar USD

Institutional shareholders

32.69%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 2018129.40m7.93%
Wellington Management Co. LLPas of 28 Feb 2019117.22m7.18%
BlackRock Fund Advisorsas of 31 Dec 201876.22m4.67%
SSgA Funds Management, Inc.as of 31 Dec 201865.93m4.04%
Dodge & Coxas of 31 Dec 201842.59m2.61%
Columbia Management Investment Advisers LLCas of 31 Dec 201825.06m1.54%
Northern Trust Investments, Inc.as of 31 Dec 201822.58m1.38%
Geode Capital Management LLCas of 31 Dec 201820.32m1.25%
PRIMECAP Management Co.as of 31 Dec 201818.58m1.14%
Norges Bank Investment Managementas of 31 Dec 201815.76m0.97%
More ▼
Data from 31 Dec 2018 - 31 Dec 2018Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.